Shan Jiang

Shan Jiang

Auto-generated profile, based on publicly available information

Shan Jiang

Department of Dermatology, Renmin Hospital of Wuhan University, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ZCZhaowei Chen
Zhaowei Chen
JHJijia Hu
Jijia Hu
ZZZongwei Zhang
Zongwei Zhang
SJShan Shan Jiang
Shan Shan Jiang
SHShoumeng Han
Shoumeng Han
ZZZhan Zhang
Zhan Zhang
Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia. Trial registration: URL: https://www.clinicaltrials.gov/ . The unique identifier: ChiCTR2000029559.

6 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ZCZhaowei Chen
Zhaowei Chen
JHJijia Hu
Jijia Hu
ZZZongwei Zhang
Zongwei Zhang
SJShan Jiang
Shan Jiang
TWTao Wang
Tao Wang
ZZZhan Zhang
Zhan Zhang
Background: With the emergence of 4 rd generation transmission, the prevention and treatment of the novel coronavirus disease 2019 (COVID-19) has entered a new period. We aimed to report several changes in the clinical characteristics at admission of patients with COVID-19. Methods: Clinical records and laboratory results of patients suffering from COVID-19 were retrospectively reviewed and matched with the admission dates to analyze the changes in characteristics at the onset of illness. Results: Of the 89 affected patients, 31 [34.8%] patients were admitted from January 16 to 22, and 58 [65.2%] were admitted from January 23 to 29. Patients were admitted with more systemic symptoms, such as fever (21 [67.7%] of 31), fatigue (13 [41.9%] of 31), and myalgia (7 [22.6%] of 31), before January 23. More patients (10 [32.3%] of 31) admitted before January 23 had a small amount of sputum production compared with a smaller proportion (4 [6.9%] of 58) of the patients admitted after January 23. Other symptoms, such as cough, nausea, diarrhea, and chest tightness, were not significantly different between the two groups. In addition, the group admitted before January 23 had a larger proportion of patients with reduced lymphocyte (13 [54.2%] of 24), CD3 (11 [54.4%] of 21), and CD8 (9 [42.9%] of 21) counts and elevated serum amyloid A (SAA, 18 [75%] of 24). Conclusions: The initial symptoms of recently infected patients seem more insidious, indicating that the new coronavirus may gradually evolve into a virus similar to influenza and latent in asymptomatic carriers for a long time. Summary: Compared with the cases admitted earlier, more hidden initial symptoms and improved immune system disorders appeared in COVID-19 patients infected recently.

1 January 2024 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
LLLin-Xia Liu
Lin-Xia Liu
ZLZhi-Kai Liao
Zhi-Kai Liao
BDBing-Qi Dong
Bing-Qi Dong
SJShan Jiang
Shan Jiang
TLTie-Chi Lei
Tie-Chi Lei
Liu LX, et al. Ann Dermatol. 2024 Apr;36:e30. https://doi.org/10.5021/ad.23.108

9 February 2024 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Open access
SJShan Jiang
Shan Jiang
XHXia Hu
Xia Hu
XPXiaoyan Peng
Xiaoyan Peng
TLTiechi Lei
Tiechi Lei
Background: Condyloma acuminatum (CA) of the vagina is a sexually transmitted disease due to infection by human papilloma virus (HPV). The treatment efficacy of the conventional methods for vaginal CA is often unsatisfactory with a high recurrence rate. Topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) combined with CO2 laser pretreatment is a feasible approach for vaginal CA, but the effectiveness and safety need further evaluation. Methods: This study enrolled 15 patients with vaginal CA. All patients underwent CO2 laser ablation and then ALA-PDT for two or three cycles. The clinical efficacy and side effects were evaluated and analyzed during the treatment and 6 months after the treatment. Results: The wart lesions in 4 cases (26.7 %) disappeared after the first treatment. The wart lesions in 5 cases (33.3 %) disappeared after the second treatment. And 6 cases (40 %) needed three treatment cycles before the lesions disappeared completely. The complete response (CR) rate was 93.3 % (14/15) at 2 weeks after three treatment cycles. There were 5 cases (83.3 %) which have complete remission after 2 treatments in warts diameter 1 cm group. All patients had CR without reoccurrence at 6 months after treatment. The side effects mainly included a mild or moderate burning or stinging sensation (26.7 %). There were no infection, ulcers and scars after treatment. Conclusion: Topical 5-aminolevulinic acid-mediated photodynamic therapy combined with CO2 laser pretreatment is a safe and effective treatment for vaginal CA.

2 December 2016 in Blood
Verified
Journal Article
Open access
YWYue Wei
Yue Wei
HZHong Zheng
Hong Zheng
YJYu Jia
Yu Jia
NBNaran Bao
Naran Bao
SJShan Jiang
Shan Jiang
GGGuillermo Garcia-Manero
Guillermo Garcia-Manero
Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)aremyeloid neoplasms characterized by abnormal bone marrow hematopoiesis and increased risk of transformation to acute myelogenous leukemia (AML). Epigenetic dysregulation and inflammatory hyper-activation have been recognized as key molecular abnormalities in the bone marrow (BM) hematopoietic stem and progenitor cells (HSPC) of MDS and CMML, which implies that key modulators of epigenetic and inflammatory regulation play an important role in the pathophysiology of these diseases, which could also serve as effective therapeutic targets. We recently identified such a candidate molecule: the histone demethylase KDM6B (JMJD3). We demonstrated that KDM6B is significantly overexpressed in the BM HSPCs of patients with MDS and CMML, and the overexpression of KDM6B mediates aberrant epigenetic activation of innate immune/inflammatory signals and consequent differentiation skewing in BM HSPCs of MDS, which can be reversed by targeting KDM6B. Importantly, systematic analysis of the global transcriptomic and genomic data of patients indicates that, although KDM6B is overexpressed in MDS and CMML, genetic lesions in this gene are very rare, and higher KDM6B expression correlates with TET2 mutation. These results imply that constitutive expression of KDM6B potentially interacts with more common genetic lesions during the development of MDS and CMML. To further investigate the effects of KDM6B overexpression on hematopoiesis and its role in myeloid disorders, we developed a novel hematopoietic KDM6B transgenic (Tg) mouse model that overexpresses KDM6B under the control of the murine hematopoietic specific Vav promoter (Vav-KDM6B). Long-term monitoring of the peripheral blood counts of the mice indicates that, although younger Vav-KDM6B mice display only minor changes in whole white blood cells (WBC), monocytes, and platelets, aged KDM6B mice (>1 year old) have significant increases of WBC (by 22%, p<0.05) and monocyte counts (by 34%, p<0.01). In BM biopsies, the megakaryocytic progenitors of Vav-KDM6B mice specifically possess dysplastic morphology. Analysis of BM HSPCs revealed a tendency of increased numbers of long-term hematopoietic stem cells (LT-HSC) in Vav-KDM6B mice. Because MDS and CMML are associated with a pro-inflammatory BM microenvironment, we applied low-dose lipopolysaccharide (LPS) treatment (6 µg/mouse) for 6 weeks to both Vav-KDM6B and control mice. After chronic immune stimulation, more significant decreases of peripheral red cell (RBC) count and hemoglobin were observed in LPS-treated Vav-KDM6B mice compared to others. In BM biopsies, we noted more dramatic increases of megakaryoblasts in LPS-treated Vav-KDM6B mice than treated wild-type mice. Increases of BM HSPCs were also detected in LPS-treated Vav-KDM6B mice, including LSK cells and LT-HSC populations. Furthermore, the LSK cells isolated from LPS-treated Vav-KDM6B mice consistently demonstrated increased serial plating capacity in methocult-supported colony formation assays. Taken together, these hematopoietic phenotypes observed in the LPS-treated Vav-KDM6B Tg mice indicate that KDM6B overexpression in combination with pro-inflammatory stimulation can accelerate the occurrence of the MDS- and CMML-like abnormalities in BM HSPCs. To gain more insight into the cellular and molecular impacts of KDM6B overexpression on BM HSPCs, detailed analysis, including in vivo repopulating capacity assays as well as gene expression profiling, are being performed.

12 November 2026 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
LZLiang Zhao
Liang Zhao
MWMeng Wang
Meng Wang
XPXiaoyan Peng
Xiaoyan Peng
JWJiaoping Wan
Jiaoping Wan
NWNaming Wu
Naming Wu
SJShan Jiang
Shan Jiang
Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive disorder mainly caused by mutations in the NTRK1 gene. Its cardinal features include insensitivity to pain, anhidrosis, recurrent fever, and self-mutilating behavior. While CIPA siblings predominantly show similar phenotypes or severity differences positively correlated with age, phenotypic divergences that are age-independent, inversely correlated with age, or affect distinct organ systems have been rarely reported in siblings with identical NTRK1 mutations. We report two Han Chinese males, aged 29 and 16 years, who carried identical compound heterozygous NTRK1 mutations (c.446_447insTCTG, p. P149fs from the father and c.2293C>T, p. R765C from the mother) but exhibited markedly different clinical manifestations: the elder brother presented with chronic elbow ulcer, severe nail damage, and partial preservation of lingual temperature sensation with mild intellectual disability, whereas the younger brother had recurrent painless fractures, severe knee joint destruction, inability to stand independently, and severe intellectual disability with relatively mild skin and soft tissue involvement. A structured literature review identified 27 CIPA sibling families, among which phenotypic differences mostly manifested as age-positive severity or age-independent phenotypes. In contrast, our siblings exhibited a rare age-inverse divergence across distinct organ systems under an identical genotype. The elder brother was predominantly affected by skin and soft tissue, whereas the younger brother suffered from severe skeletal complications. This phenotypic divergence is unlikely to be fully explained by age or cumulative injury alone. These findings highlight this unexpected age-inverse phenotypic divergence among siblings with identical NTRK1 genotype, emphasizing the need for independent, comprehensive multi-organ assessments for each CIPA patient rather than predicting disease patterns in siblings solely based on the proband’s phenotype.